Multiple Sclerosis, Rituximab, Hypogammaglobulinemia and Risk of Infections
Release Date:
Dr. Shuvro Roy and Dr. Annette Langer-Gould discuss the effective dose of rituximab and other B-cell depleting therapies in patients with multiple sclerosis, as well as important comorbidities to prevent infection risks. Show reference: https://www.neurology.org/doi/10.1212/NXI.0000000000200211
Multiple Sclerosis, Rituximab, Hypogammaglobulinemia and Risk of Infections